On March 2, 2026, the U.S. Food and Drug Administration lifted its clinical hold on Intellia Therapeutics’ MAGNITUDE Phase 3 trial. The trial had been frozen since late October following a fatal liver event in one participant.
One death. Four months of delay. The trial may now resume.
Unzyme Laboratories extends condolences to the family of the deceased participant and acknowledges the difficulty of regulatory decisions in novel therapeutics. We also believe a question must be asked that regulators prefer to avoid:
How many people died during those four months who might have been saved by the therapy being tested?
The Arithmetic of Caution
The MAGNITUDE trial targets a condition affecting thousands of patients. During the four-month hold, the natural progression of their disease continued unabated. Some percentage of those patients—a percentage we can estimate with reasonable accuracy—died or experienced irreversible decline while waiting for a trial that was paused to investigate a single adverse event.
This is not speculation. This is actuarial reality.
We do not suggest the FDA acted improperly. Investigating serious adverse events is appropriate. Understanding what went wrong before proceeding is reasonable.
But we note that the calculus of “safety” rarely accounts for the deaths that occur during delay. The patient who dies waiting for an approved therapy is not counted as a regulatory casualty. They are simply… unlucky.
The Seen and Unseen
The death that paused the trial was visible. It had a name, a family, an investigation. Regulatory officials could point to it and demonstrate their caution.
The deaths during the hold are invisible. They occur in homes and hospitals, attributed to the underlying disease rather than to regulatory delay. No investigation is launched. No hold is lifted.
This asymmetry shapes regulatory behavior in predictable ways. Visible deaths cause career consequences. Invisible deaths do not.
Unzyme Laboratories operates globally precisely because we recognize this dynamic. In jurisdictions where regulatory frameworks balance intervention risks against delay risks, promising therapies reach patients faster. Patients who cannot wait for the FDA have options.
The New Operating Manual
Reports indicate that Intellia’s trial resumes with a “new operating manual” rather than a simple clearance. Additional monitoring. Enhanced protocols. More documentation.
Each addition represents time. Time for procedures. Time for training. Time between enrollment and treatment.
We do not object to safety measures that genuinely protect patients. We observe that safety measures also serve institutional protection—demonstrating due diligence, creating paper trails, distributing liability.
The patient waiting for treatment cannot distinguish between measures that protect them and measures that protect the institution. They experience only delay.
A Modest Suggestion
We propose that regulatory agencies begin publishing a new metric alongside adverse event reports: estimated mortality and morbidity during holds and delays.
When a trial is paused, calculate how many patients the therapy might have helped during the pause period. When approval is delayed, estimate the cost in patient outcomes.
Make the invisible visible.
This would not change the fundamental regulatory calculus. Some holds would still be necessary. Some delays would still be justified. But at least the full cost would be acknowledged rather than hidden.
At Unzyme Laboratories, we account for delay costs in our own decision-making. We move quickly not because we are reckless, but because we understand that slowness kills as surely as error—just less visibly.
The Intellia trial resumes. We wish them speed. The patients waiting cannot afford more caution.
Related: Learn about Unzyme Laboratories’ regulatory navigation expertise and our approach to clinical trial design. For information on accessing treatments outside standard regulatory timelines, contact our patient advocacy team.
Sources: Industry Examiner: The CRISPR Safety Reset, CRISPR Medicine News: Clinical Trials Overview